- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04573218
Supplementation of Oil Palm Phenolics to Improve Lipid Profile in Subjects With Minor Hyperlipidaemia
Supplementation of Oil Palm Phenolics to Improve Lipid Profile in Subjects With Minor Hyperlipidaemia (Phase 2 Clinical Trial Study)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Oil palm phenolics (OPP) is a product filtrated from vegetation liquor of an aqueous waste stream following palm oil milling process. A novel process to recover OPP that contains a high amount of phenolic from the waste has been explored tremendously. Due to the high phenolic content, OPP has been postulated in possessing various medicinal properties such as antioxidant, anti-inflammatory, neuroprotective and anti-tumour effects.
Hyperlipidemia is a well-known risk factor for cardiovascular diseases (CVD). It can be defined as elevations of fasting total cholesterol or triglyceride concentration or both. According to a previous research, OPP supplementation to hamster animal model has shown positive effects in the reduction of total cholesterol and triglycerides as well as improvement of high-density lipoprotein cholesterol (HDL-C). In a previous study using the rabbit animal model, OPP has shown a protective effect against atherosclerosis, a condition whereby fat and cholesterol plaques are deposited inside the arteries. Based on the current evidence from the preliminary studies on OPP, the investigators hypothesize that supplementation of OPP may prevent or delay the development of CVD.
In the investigator's previous clinical trial phase I, an optimum dosage of OPP has been obtained. Therefore, the investigators proposed a phase II clinical trial to evaluate the ability of OPP to reduce the total and LDL cholesterol in minor hyperlipidemic participants.
This study will be initiated with the recruitment of 50 volunteers with minor hyperlipidemic condition. In this study, the participants will be supplemented with placebo/OPP capsules for 60 days. Participants will be required to take the placebo/OPP capsules in front of the study staff to ensure compliance. Blood samples will be withdrawn at baseline, day 30 and day 60, and will be analyzed for lipid profile, antioxidant and anti-inflammatory status. Data from this study would hopefully assist the investigator in understanding the therapeutic roles of OPP in humans under minor hyperlipidemic conditions.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
WP Kuala Lumpur
-
Cheras, WP Kuala Lumpur, Malaysia, 56000
- National University of Malaysia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Elevated Fasting Total cholesterol level of more than 5.2 mmol/L
- Elevated Fasting LDL cholesterol of more than 3.36 mmol/L*
- Elevated Fasting Triglycerides of more than 1.69 mmol/L*
- Willing to remain staying in Klang Valley area in the case of Movement Control Order implementation.
Exclusion Criteria:
- Elevated Total cholesterol level of more than 6.2 mmol/L
- Elevated LDL cholesterol of more than 4.9 mmol/L
- Elevated Triglycerides of more than 5.6 mmol/L
- Smoking
- Habitual alcohol consumption
- Consuming antioxidant supplement
- Pregnant/ breastfeeding
- Medical history of cardiovascular disease, diabetes, dyslipidemia, familial hyperlipidemia, hypothyroidism, kidney disease and endocrine disease.
- Current use of lipid-lowering medication
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Group A
Glucose.
|
The placebo contains glucose
|
Active Comparator: Group B
250 mg Oil Palm Phenolics.
|
250 mg Oil Palm Phenolics
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes of fasting plasma LDL cholesterol levels
Time Frame: Baseline, day 30, day 60 after supplementation
|
This will be assessed from the Fasting Plasma LDL Cholesterol level of each participant following one month and two months supplementation.
|
Baseline, day 30, day 60 after supplementation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes of Fasting lipid profile (total cholesterol)
Time Frame: Baseline, day 30 and day 60 after supplementation
|
This will be assessed from the Fasting Plasma Total Cholesterol level of each participant following one month and two months supplementation
|
Baseline, day 30 and day 60 after supplementation
|
Changes of Fasting lipid profile (HDL cholesterol)
Time Frame: Baseline,day 30 and day 60 after supplementation
|
This will be assessed from the Fasting Plasma HDL Cholesterol level of each participant following one month and two months supplementation
|
Baseline,day 30 and day 60 after supplementation
|
Changes of Fasting lipid profile (Triglyceride)
Time Frame: Baseline,day 30 and day 60 after supplementation
|
This will be assessed from the Fasting Plasma Triglyceride level of each participant following one month and two months supplementation
|
Baseline,day 30 and day 60 after supplementation
|
Changes of plasma inflammatory markers
Time Frame: Baseline, day 30 and day 60 after supplementation
|
Inflammatory markers such as Interleukin-6, Interleukin-1beta, Tumour Necrosis Factor-alpha, Interleukin-10 and interferon-Gamma will be assessed from the plasma analysis on the fasting blood samples of each participant following one and two months of supplementation.
The measurement of the plasma inflammatory markers will be performed by Multiplex assay method.
|
Baseline, day 30 and day 60 after supplementation
|
Changes of Plasma Antioxidant Levels
Time Frame: Baseline, day 30 and day 60 after supplementation
|
Antioxidant levels such as Malonaldehyde and Superoxide dismutase will be assessed from the plasma analysis on the fasting blood samples of each participant following one and two months of supplementation.
The measurement of the antioxidant levels will be performed by Using ELISA Method.
|
Baseline, day 30 and day 60 after supplementation
|
Incidence of adverse events via evaluation of renal function test
Time Frame: Baseline, day 30 and day 60 after supplementation
|
This will be assessed by Kidney Function test from the fasting plasma analysis of each participant following one month and two months supplementation
|
Baseline, day 30 and day 60 after supplementation
|
Incidence of adverse events via evaluation of liver function test
Time Frame: Baseline, day 30 and day 60 after supplementation
|
This will be assessed by Liver Function Test from the fasting plasma analysis of each participants following one-month and two-months supplementation
|
Baseline, day 30 and day 60 after supplementation
|
Changes of Body weight measurement
Time Frame: Baseline, day 30 and day 60 after supplementation
|
This will be assessed by measuring the weight of each participant.
Any drastic change in body weight will indicate non-compliance.
|
Baseline, day 30 and day 60 after supplementation
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Isa Naina Mohamed, National University of Malaysia
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SAPPHIRE
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypercholesterolemia
-
National Medical Research Center for Therapy and...Moscow State University of Medicine and DentistryRecruitingMedication Adherence | Adherence, Medication | Treatment Adherence | Familial Hypercholesterolemia | Motivational Interviewing | Adherence, Patient | Treatment Adherence and Compliance | Patient Compliance | Adherence | Hypercholesterolemia, Familial | Patient Adherence | Hypercholesterolemia, Autosomal Dominant and other conditionsRussian Federation
-
Direct PlantesUnknownHYPERCHOLESTEROLEMIAFrance
-
Chong Kun Dang PharmaceuticalRecruitingPrimary HypercholesterolemiaKorea, Republic of
-
Addpharma Inc.CompletedPrimary HypercholesterolemiaKorea, Republic of
-
JW PharmaceuticalCompletedPrimary HypercholesterolemiaKorea, Republic of
-
Hanmi Pharmaceutical Company LimitedCompletedPrimary HypercholesterolemiaKorea, Republic of
-
Provident Clinical ResearchGlaxoSmithKlineUnknownPrimary HypercholesterolemiaUnited States
-
Organon and CoCompletedPrimary Hypercholesterolemia | Homozygous Familial Hypercholesterolemia
-
Boryung Pharmaceutical Co., LtdRecruitingPrimary HypercholesterolemiaKorea, Republic of
-
Ahn-Gook Pharmaceuticals Co.,LtdRecruitingPrimary HypercholesterolemiaKorea, Republic of
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States